The newly described TGF-β/Smad1 signaling axis has been reported to be inactivated in more than 85% of DLBCL patients, and DLBCL cell lines lacking Smad1 exhibit a strong growth advantage30. This evidence concerns the gene SMAD1 and diffuse large B-cell lymphoma.